BioSphere Medical, Inc. To Present at Wall Street Analyst Forum.Business Editors/Health/Medical Writers Wall Street Analyst Forum ROCKLAND, Mass.--(BUSINESS WIRE)--Nov. 6, 2003 BioSphere Medical, Inc. (Nasdaq: BSMD) announced today that they will be presenting at the Wall Street Analyst Forum in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on Tuesday, November 11, 2003. The conference is being held at the Roosevelt Hotel at Madison Avenue & 45th. For more information on the conference or to receive a copy of the conference schedule, please contact The Wall Street Analyst Forum at 802-253-7596. The presentation will be given at 11:40AM (E.T.) by Robert M. Palladino, Executive Vice President and CFO See Chief Financial Officer. and will be immediately followed by a 40-minute breakout session. A direct link to the audio portion of the live presentation can be accessed at BioSphere Medical's website (www.biospheremed.com). To ensure a timely connection to the live webcast, it is recommended that participants register at least 10 minutes prior to the start. An archived audio webcast also will be available from Tuesday, November 11th through Tuesday, November 18th. Please note, the breakout session will not be available via webcast. About BioSphere Medical, Inc. BioSphere Medical, Inc., based in Rockland, Massachusetts, is a medical device company focused on applying our proprietary microsphere Not to be confused with Glass microphere. This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life. technology to medical applications using embolotherapy techniques. Our core technologies, patented bio-engineered polymers and manufacturing methods, are used to produce miniature spherical beads with uniquely beneficial properties for a variety of medical applications. Our principal focus is the treatment of symptomatic uterine fibroids Uterine Fibroids Definition Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer. using a procedure called uterine fibroid embolization Uterine Fibroid Embolization Definition Uterine fibroids are growths in the muscular tissue of the womb (uterus). Uterine fibroid embolization is non-surgical removal of the growths through the use of a tubular device called a catheter. , or UFE UFE Uterine Fibroid Embolization UFE United for a Fair Economy UFE Ufficio Federale dell'Energia UFE Uniform Final Examination UFE Urban Challenge Final Event (DARPA) UFE Unidentified Flags and Ensigns UFE Unrestricted Free Agent . Our products are already beginning to gain acceptance in this rapidly emerging procedure as well as in a number of other, new and established medical treatments. Our strategy is two fold. First, we are seeking to grow the embolotherapy business worldwide, specifically the UFE procedure, by increasing awareness of availability of this procedure. Second, we are seeking to maintain our current technology leadership by the continuous introduction of new products and product improvements, both through internally developed and externally acquired technologies, that improve and broaden the use of embolotherapy techniques. Cautionary Statement Regarding Forward-Looking Statements - This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, including statements with respect to the company's expectations that it will successfully promote awareness and market and sell its products through its sales, marketing and education programs and achieve its objectives with respect to revenue and profitability. These risk factors are further detailed in the in the Company's report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002 and Form 10-Q Form 10-Q See 10-Q. for the quarter ended June 30, 2003. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion